千万级天使轮融资！前列腺增生微创治疗设备

Core Viewpoint - Suzhou Feima Medical Technology Co., Ltd. has completed a multi-million RMB angel round financing led by Yirui Star Capital, which will primarily fund clinical trials, registration approvals, and industrialization of its core product, the freedomax™ steam ablation system [2][12]. Industry Background - Benign Prostatic Hyperplasia (BPH) is a common urological condition among elderly men, with incidence rates increasing significantly with age. Symptoms include frequent urination, urgency, difficulty urinating, and interrupted urine flow, severely impacting quality of life. The aging population in China is exacerbating the social and medical burden of BPH [3]. - Traditional treatments for BPH include medication and surgical options. While medications can improve mild to moderate symptoms, they have long-term efficacy and compliance issues. Classic surgical methods, such as Transurethral Resection of the Prostate (TURP), are effective but come with significant drawbacks, including high trauma, slow recovery, bleeding, and sexual function complications [3]. Company Overview - Feima Medical was established in 2023, focusing on developing minimally invasive treatment devices for male urological health that meet Chinese clinical needs. The founding team has extensive backgrounds in high-value medical devices from renowned companies like Medtronic, Johnson & Johnson, and MicroPort, with experience in RF ablation, ultrasound knives, and implantable devices [8]. - The company's strategy emphasizes a dual-track development of "urological treatment devices + daily care products," aiming to create a comprehensive ecosystem for urological health that covers treatment, rehabilitation, and long-term management, thereby enhancing long-term resilience and market value [8]. Product Introduction - The freedomax™ is an independently developed steam ablation system targeting BPH. Its core technology includes a radiofrequency heating module, injection module, and intelligent control algorithm, which heats water into steam and precisely injects it into the prostatic tissue via a urethral catheter, causing necrosis and alleviating urethral pressure [10]. - Compared to traditional resection and some laser/electrocution surgeries, freedomax™ offers advantages such as minimal trauma, quick recovery, preservation of urethral structure, good postoperative sexual function retention, and low complication rates. The system has shown good safety and efficacy in preclinical and animal studies, with significant reductions in prostate volume and no notable complications. Multi-center clinical trials are being prepared, with market launch expected in 2027 [10]. Financing Purpose - The recent financing will be primarily used for accelerating registration, industrialization, and market layout. The founder expressed gratitude for the support from Yirui Star Capital and emphasized the commitment to innovative, minimally invasive urological products that will benefit patients [12]. - Yirui Star Capital noted that the treatment of BPH is entering an "ultra-minimally invasive era," with new technologies like steam ablation showing significant advantages in surgical duration and postoperative function retention. The Feima Medical team has achieved several industry-first innovations and possesses complete capabilities from R&D to commercialization, with potential for continued impact in male health and elderly care sectors [12]. Conclusion - In the context of accelerating global developments in minimally invasive treatments, Feima Medical's steam ablation system represents a breakthrough in domestic innovation. By continuously deepening its focus on technology, team, and product pipeline, the company is facilitating the transition of Chinese urological minimally invasive treatments from importation to independent innovation [13]. - As clinical progress and registration materialize, Feima Medical is expected to fill a domestic market gap, promoting steam ablation technology to benefit more patients and ushering in a new era of elderly male health management [13].